MedTrace Logo

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

NCT02750514 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 295

Last updated 2021-03-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

Conditions

Interventions

BIOLOGICAL

Nivolumab

Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.

DRUG

Dasatinib

BIOLOGICAL

Relatlimab

BIOLOGICAL

Ipilimumab

DRUG

BMS-986205

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-09
Primary Completion
2020-01-29
Completion
2020-01-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • France
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02750514 on ClinicalTrials.gov